← back to search

Ann‐Kathrin Bittner

Twitter (United States) · US
Area of research
Radiology, Nuclear Medicine and Imaging · Cancer Research
Research interest
Research focused on Breast cancer and Hazard ratio, with related work in RANKL, Periostin, Proportional hazards model. Notable publications include 'Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis', 'Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer', and 'High serum levels of periostin are associated with a poor survival in breast cancer'.
h-index
citations
157
works
5
NIH funding
primary concept
email

Recent publications

High serum levels of leucine-rich α-2 glycoprotein 1 (LRG-1) are associated with poor survival in patients with early breast cancer
Archives of Gynecology and Obstetrics 2024cited by 8position: lastdoi
Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis
European Journal of Cancer 2021cited by 50position: middledoi
Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer
Journal of Cancer Research and Clinical Oncology 2021cited by 27position: lastdoi
High serum levels of periostin are associated with a poor survival in breast cancer
Breast Cancer Research and Treatment 2020cited by 29position: lastdoi
Prognostic Value of RANKL/OPG Serum Levels and Disseminated Tumor Cells in Nonmetastatic Breast Cancer
Clinical Cancer Research 2018cited by 43position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Oliver Hoffmann · National Center for Tumor Diseases4 papers (2018–2024)Tilman D. Rachner · German Cancer Research Center4 papers (2018–2024)Sabine Kasimir‐Bauer · Essen University Hospital4 papers (2018–2024)Lorenz C. Hofbauer · Institute of Aging4 papers (2018–2024)Rainer Kimmig · National Center for Tumor Diseases4 papers (2018–2024)Kati Erdmann · Klinik und Poliklinik für Urologie3 papers (2018–2021)Andy Göbel · German Cancer Research Center3 papers (2018–2024)Martina Rauner · Ferro (United States)2 papers (2018–2021)Daniel Martin Klotz · Boehringer Ingelheim (China)1 papers (2024–2024)Dorit Breining · Technische Universität Dresden1 papers (2020–2020)Pauline Wimberger · Kliniken Essen-Mitte1 papers (2018–2018)Andrew Browne · University of California, Irvine1 papers (2018–2018)